Freedom Investment Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Freedom Investment Management’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,586	Closed	-$206K	–	683
2023 Q2	$206K	Buy	+3,586	New	+$159K	0.02%	646
2022 Q2	–	Sell	-8,556	Closed	-$307K	–	734
2022 Q1	$307K	Buy	+8,556	New	+$243K	0.03%	609
2018 Q2	–	Sell	-21,206	Closed	-$398K	–	952
2018 Q1	$398K	Buy	+21,206	New	+$399K	0.02%	756
2017 Q1	–	Sell	-12,898	Closed	-$238K	–	1053
2016 Q4	$238K	Buy	+12,898	New	+$251K	0.01%	801

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Freedom Investment Management's AMPH Position: Q3 2023 in Review

Freedom Investment Management sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2023, closing a stake of 3,586 shares — an estimated $206K sold.

Freedom Investment Management first reported a position in AMPH in Q4 2016 and held it in 4 quarters. The position peaked at $398K in Q1 2018. 255 funds tracked by Wall St. Rank hold AMPH as of Q3 2023.

Freedom Investment Management reported no remaining Amphastar Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Freedom Investment Management sold 3,586 Amphastar Pharmaceuticals shares in Q3 2023, an estimated $206K.
Freedom Investment Management first reported a position in Amphastar Pharmaceuticals in Q4 2016 and held it in 4 quarters.
Freedom Investment Management's Amphastar Pharmaceuticals position peaked at $398K in Q1 2018.
255 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2023.

Based on Freedom Investment Management's 13F filing for Q3 2023, filed 13 Nov 2023.